Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more

Conditions: Parkinson Disease, Depression
Interventions: OnabotulinumtoxinA, Control; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Congenital Hyperinsulinism
Interventions: Exendin (9-39), Vehicle; Drug
Lead sponsor: Diva De Leon; Other
Eligibility: Up to 12 Months
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypogammaglobulinemia, Bacterial Infections, B-cell Chronic Lymphocytic Leukemia, Multiple Myleoma, Non-Hodgkin Lymphoma
Interventions: Xembify, Placebo; Drug
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 9
States / cities: Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more

Conditions: HIV -1 Infection
Interventions: BNT168, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tibial Meniscus Injuries, Knee Injuries, Knee Injuries and Disorders
Interventions: Lipogems, Normal Saline; Device · Drug
Lead sponsor: Kessler Foundation; Other
Eligibility: 18 Years to 45 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: West Orange, New Jersey

Conditions: Healthy Volunteers, Obesity
Interventions: Ghrelin, Saline; Drug
Lead sponsor: Jenny Tong, MD, MPH; Other
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Postoperative, Morbid Obesity
Interventions: Injected bupivacaine post-operatively, Streamed bupivacaine versus streamed normal saline, Aerosolized bupivacaine versus aerosolized saline, Injected lidocaine pre-incision vs saline pre-incision; Drug
Lead sponsor: Pinnacle Health System; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Harrisburg, Pennsylvania

Conditions: Hypertension
Interventions: Saline, QCZ484; Other · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 63
States / cities: Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 58 more

Conditions: Head Injury, Minor, Pediatric, Emergency Department Patient
Interventions: Hypertonic Saline ( 3% Sodium Chloride Saline), Normal Saline (0.9% NaCl); Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 8 Years to 17 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: DENV-3 Controlled Human Infection Model
Interventions: AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Baltimore, Maryland • Burlington, Vermont

Conditions: SARS-CoV-2
Interventions: mRNA-1283, mRNA-1273, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Chandler, Arizona • San Diego, California • Melbourne, Florida + 2 more

Conditions: Ankle Osteoarthritis
Interventions: Axolotl Ambient, "Drug/Placebo: 0.9% Normal Saline"; Biological · Drug
Lead sponsor: Axolotl Biologix; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Boise, Idaho • Shreveport, Louisiana • Charlotte, North Carolina

Conditions: Human Immunodeficiency Virus
Interventions: 3BNC117, 10-1074, Placebo; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Respiratory Distress Syndrome, Adult
Interventions: Albuterol Sulfate, Mini-Bronchoalveolar Lavage (BAL), Placebo; Drug · Procedure
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 13 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 40
States / cities: Fresno, California • Sacramento, California • San Francisco, California + 19 more

Conditions: Hyperalgesia, Secondary
Interventions: Bupivacaine Placebo, Clonidine Placebo, Bupivacaine, Clonidine; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer Female
Interventions: Bupivacaine Hydrochloride, Placebo Drug, Pulsed Electromagnetic Field (PEMF) Device, Placebo Device, Ropivacaine Hydrochloride; Drug · Other · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Postoperative
Interventions: ropivacaine; Drug
Lead sponsor: Liberman, Eric, D.O.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: Healthy
Interventions: Ad26.ZEBOV-Batch #1, Ad26.ZEBOV-Batch #2, Ad26.ZEBOV-Batch #3, MVA-BN-Filo, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 329 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy
Interventions: Intravenous immunoglobulin, 0.9% Sodium Chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Shock, Traumatic
Interventions: 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more

Conditions: Peripheral Arterial Disease
Interventions: Angiotensin 1-7, Saline; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Insulin, Asp(B28)-, Glucagon, Placebo; Drug
Lead sponsor: Legacy Health System; Other
Eligibility: 21 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Radiocontrast Nephropathy
Interventions: N-Acetylcysteine (NAC), 0.9% Sodium-chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV

Ultrasound-Guided Injections for Meniscal Injuries in Active-Duty Military

Effect of Ghrelin on Decision-Making

Clinical Proposal for the Comparison of Intraperitoneal Anesthetic to Injected Local Anesthetic

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Hypertonic Saline for Mild TBI in Pediatric Patients

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis

3BNC117 and 10-1074 in HIV Uninfected Adults

Drug Study of Albuterol to Treat Acute Lung Injury

Transversus Abdominis Plane (TAP) Block for Cesarean Section

PEMF and PEC Blocks in Mastectomy Reconstruction Patients

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3

Hypertonic Resuscitation Following Traumatic Injury

Angiotensin-(1-7) in Peripheral Arterial Disease

Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients